Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Bardoxolone Methyl on Residual Renal Function in ESRD Patients with Type 2 Diabetes on Peritoneal Dialysis
2012-001563-78Phase 2Terminated
- Sponsor
- Reata Pharmaceuticals
- Start
- May 2012
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in end-stage kidney disease (ESKD), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Bardoxolone methyl 20 mg with Placebo (2 arms). Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started May 2012; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
end-stage kidney disease (ESKD)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-001563-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001563-78.